Alembic Pharmaceuticals Reports Q1 FY26 Profit After Tax at Rs. 154 Cr, Up by 15%

Alembic Pharmaceuticals Limited reported its consolidated financial results for the first quarter ended 30' June 2025. The company's revenue increased by 10% to Rs.1,711 Cr. EBITDA was up by 20% to Rs. 288 Cr. EBITDA Margin was at 17% of Revenue. Profit Before Tax was up by 21% to Rs.191 Cr. Net Profit was at Rs.154 Cr., up by 15%. The India Branded Business delivered a 5% YoY growth, reaching 599 Cr in revenue for the quarter. The US Generics grew by 13% to Rs. 523 Cr. for the quarter. Ex-US International Generics grew by 21% to Rs. 328 Cr. for the quarter. API business grew by 1% to Rs. 261 Cr. for the quarter.